证券日报网讯 2月4日，诺诚健华在互动平台回答投资者提问时表示，公司上市以来管线推进迅速，营 业收入实现加速增长，根据公司业绩预告，公司预计2025年度首次实现扭亏为盈，预计2025年实现营业 总收入人民币23.65亿元左右，与上年同期相比增长134%左右，归属于母公司所有者的净利润为6.33亿 元左右。同时，公司对于未来药品销售、管线进展及商业化合作充满信心。二级市场股价受多种因素影 响，请您注意投资风险。 （文章来源：证券日报） ...

Core Insights - Nuo Cheng Jian Hua reported a significant revenue growth of 129.9% year-on-year for Q1 2025, reaching 380 million yuan, driven by the strong performance of its core product, Oubutini, and a licensing agreement with Prolium [1] - The revenue from Oubutini increased by 89.2% year-on-year to 310 million yuan, primarily due to the inclusion of three major indications in medical insurance and enhanced execution by the commercialization team [1] - The gross profit margin improved by 5.1 percentage points year-on-year to 90.5%, with a net profit of 14 million yuan for Q1 2025, marking a profitable quarter [1] - As of March 31, 2025, the company held approximately 7.78 billion yuan in cash and cash equivalents, which will support the acceleration of multiple Phase III clinical trials and investments in differentiated ADCs and other pipelines [1] Company Developments - The CEO, Dr. Cui Jisong, highlighted that 2025 marks the 10th anniversary of the company's development, celebrating a strong start in Q1 with breakthroughs in internationalization and sustained commercialization growth [2] - The company aims to enhance its innovation, commercialization, and internationalization efforts, accelerating multiple Phase III clinical studies in China and globally to benefit more patients [2]